To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano The U.S. biotechs, which are independent but share founders and investors, raise a combined $94.5 million from the Russian sovereign fund and U.S. venture firms. read more
Exelixis' Cabozantinib Targets Particularly Sick Thyroid Cancer Patients Progression-free survival benefit in Phase III trial of rare medullary thyroid cancer was even better than expected, though full safety results are needed to flesh out the drug's profile. read more
License To Phase I Syk Inhibitor Brings Portola $36 Million Upfront In a lucrative deal with Biogen Idec, Portola also gets a $9 million equity investment, up to $508.5 million in milestones and a co-promotion option, with Biogen assuming most of the development costs. read more
Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix? The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality. read more
AstraZeneca Prepares For U.S. Statin Market Shake-Up As Lipitor Goes Generic Pricing pressure on AstraZeneca's Crestor expected from the arrival of generic atorvastatin in the U.S. in the fourth quarter. read more
State Medicaid Programs Are Increasingly Tightening Controls On Specialty Rx, Survey Finds Kaiser Family Foundation releases results of a survey of Medicaid programs Oct. 27. read more
FDA's Spielberg Wants NIH/FDA Collaborations To Focus On Problem-Solving NIH research could help FDA overcome pressing scientific hurdles and provide a rational basis for regulatory decision-making, the agency's new deputy commissioner for medical products and tobacco tells the Alliance for a Stronger FDA. read more
"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here
